Jesse Koskey, MD.

Research Update

Mood Switching in Bipolar Disorder

May 1, 2024

Jesse Koskey, MD. Dr. Koskey has no financial relationships with companies related to this material.

Researchers delve into the occurrence of mood switches in bipolar disorder, and consider both manic and depressive episodes.

Research Update

Powering Up the Brain: tDCS for ADHD?

April 1, 2024

Jesse Koskey, MD.

Jesse Koskey, MD. Dr. Koskey has no financial relationships with companies related to this material.

A popular DIY therapy for depression (transcranial direct current stimulation) is tested in ADHD.

Clinical Update

Controlled Substances: Handling Red Flags

October 3, 2023

Jesse Koskey, MD.

Jesse Koskey, MD. Associate Clinical Professor, Department of Psychiatry and Behavioral Sciences, UC Davis Health.Dr. Koskey has no financial relationships with companies related to this material.

It’s a dilemma that will challenge the most seasoned psychopharmacologist: “My Adderall spilled down the sink.” We clarify how to respond in the post-lockdown landscape.

Psychiatry Practice Boosters, Fourth Edition (2023)

PDF/eBook, CME Post-Test, and Study Guide Access

July 18, 2023

Jesse Koskey, MD. and Zachary Davis

Dr. Koskey and Mr. Davis have no relevant financial relationship(s) with ineligible companies to disclose.

Teaches you the key points of 63 of the most clinically relevant studies in psychiatry published between 2021 and 2023. Includes a 10 CME Post-Test.

Psychiatry Practice Boosters, Fourth Edition (2023)

PDF/eBook, CME Post-Test, and Study Guide Access

July 18, 2023

Jesse Koskey, MD. and Zachary Davis

Dr. Koskey and Mr. Davis have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Teaches you the key points of 63 of the most clinically relevant studies in psychiatry published between 2021 and 2023. Includes a 10 CME Post-Test.

Clinical Update

Music for Sleep

April 14, 2023

Jesse Koskey, MD.

Jesse Koskey, MD. Associate Clinical Professor, Department of Psychiatry and Behavioral Sciences, UC Davis Health, Sacramento, CA.

Dr. Koskey has no financial relationships with companies related to this material.

An alternative to hypnotics with a surprising effect size.

A Prescription App for Insomnia

March 4, 2022

Jesse Koskey, MD.

Jesse Koskey, MD. Psychiatrist at Sensible Care, CA Dr. Koskey has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Psychiatrists can now prescribe a cognitive behavioral therapy app that takes basic therapy one step further with digital adaptions to improve insomnia, sleep apnea, and mood.

Faith and Addiction

October 21, 2020

Jesse Koskey, MD.

Jesse Koskey, MD. Psychiatrist at Kaiser Permanente, CA. Dr. Koskey has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Faith may be a protective factor against addiction, and some widely accepted treatments use faith to build recovery capacity. This article reviews the evidence for faith-based treatment and provides suggestions for incorporating faith in the clinic.

A Timely Look at Community Reinforcement for Seniors With Unhealthy Alcohol Use

October 21, 2020

Jesse Koskey, MD.

Jesse Koskey, MD. Dr. Koskey has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Interventions that combat isolation may be particularly important in the context of current physical distancing recommendations. This randomized trial tested whether community reinforcement paired with motivational enhancement therapy impacted outcomes among seniors with alcohol use disorder.

Guanfacine ER for Adults With ADHD?

October 6, 2020

Jesse Koskey, MD.

Jesse Koskey, MD. Dr. Koskey has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Children and adults respond differently to medications for ADHD. This first-of-its-kind trial tested out the pediatric-approved guanfacine ER (Intuniv) in adult ADHD.